Skip to main content

Dr. Jeffrey H. Margolis, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
33
In the NPI registry since
2005
Medicare patients seen, 2024
898

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1993Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    MI license 4301075311

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
898
Services billed
385,662
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram46,02011
Injection, pembrolizumab, 1 mg29,60024
Injection, fosaprepitant, 1 mg28,50048
Injection, oxaliplatin, 0.5 mg24,10015
Injection, denosumab, 1 mg18,12081
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)17,34019
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units12,00054
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg6,66412
Injection, dexamethasone sodium phosphate, 1 mg5,39883
Injection, palonosetron hcl, 25 mcg3,20072

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 3 payments worth $288 in total to this clinician.

By company
Genmab U.S., Inc.$132
Avyxa Pharma, LLC$132
Sumitomo Pharma America, Inc.$24.30
By type
Food and Beverage$264
Education$24.30

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 14, 2025Sumitomo Pharma America, Inc.
May 14, 2025
Education
ORGOVYX · PROSTATE CANCER · in-kind
$24.30

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Michigan →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $462,993 in research payments for these studies, mostly to the institutions running them.

  • An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Part…
    Merck Sharp & Dohme LLC
  • A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adeno…
    AstraZeneca Pharmaceuticals LP
  • A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treat…
    AstraZeneca Pharmaceuticals LP
  • A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
    Genzyme Corporation · Active, not recruiting · NCT06356571
  • A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with loc…
    Bayer HealthCare Pharmaceuticals Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Madison Heights

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 18, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1871577544. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.